PERSPECTIVE
In its November 3 update, BioNTech said it had initiated early termination of a randomized Phase 2 study of autogene cevumeran, an individualized mRNA cancer vaccine developed with Genentech. The study compared the vaccine with observation after surgery and chemotherapy in patients with resected high-risk stage II or stage III colorectal cancer and detectable circulating tumor DNA.
This trial asked whether the vaccine could change what happens after a positive blood test in a population at high risk of recurrence. For developers of both molecular residual disease tests and adjuvant therapies, that distinction matters. A test can identify patients at elevated risk, while the value of acting on the result depends on the intervention and the outcomes it delivers.
BioNTech gave no reason for the termination or comparative results in the update. The company said a separate Phase 2 pancreatic cancer study of the vaccine in combination with checkpoint inhibition and chemotherapy continues.
ORIGINAL SOURCES